16 results on '"Galula, G."'
Search Results
2. Fatal herpetic hepatitis in adult following short corticotherapy: a case report
- Author
-
Seksik, P., Gozlan, J., Guitton, C., Galula, G., Maury, E., and Offenstadt, G.
- Published
- 1999
- Full Text
- View/download PDF
3. SIOG2023-4-P-288 - Short to mid-term mortality after COVID-19 pandemic in older patients with a digestive system cancer.
- Author
-
Layese, R., Aparicio, T., Hemery, F., Tournigand, C., Paillaud, E., De'angelis, N., Quero, L., Carrie, N., Prat, F., Patchev, A., Galula, G., Benderra, M.A., and Canoui-Poitrine, F.
- Published
- 2023
- Full Text
- View/download PDF
4. Impact of a pharmaceutical consultation: Review of a pilot study
- Author
-
Clou, E., primary, Gaudas, J., additional, Ahmed, K., additional, Avenin, D., additional, Esteso, A., additional, Galula, G., additional, Fillon, J., additional, Lotz, J.P., additional, and Debrix, I., additional
- Published
- 2017
- Full Text
- View/download PDF
5. 28P - Impact of a pharmaceutical consultation: Review of a pilot study
- Author
-
Clou, E., Gaudas, J., Ahmed, K., Avenin, D., Esteso, A., Galula, G., Fillon, J., Lotz, J.P., and Debrix, I.
- Published
- 2017
- Full Text
- View/download PDF
6. No changes in clinical presentation, treatment strategies and survival of pancreatic cancer cases during the SARS-COV-2 outbreak: A retrospective multicenter cohort study on real-world data.
- Author
-
Kempf E, Priou S, Lamé G, Laurent A, Guével E, Tzedakis S, Bey R, Fuks D, Chatellier G, Tannier X, Galula G, Flicoteaux R, Daniel C, and Tournigand C
- Subjects
- Humans, SARS-CoV-2, Cohort Studies, Communicable Disease Control, Retrospective Studies, Pancreatic Neoplasms, COVID-19 epidemiology, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms therapy
- Abstract
The SARS-COV-2 pandemic disrupted healthcare systems. We assessed its impact on the presentation, care trajectories and outcomes of new pancreatic cancers (PCs) in the Paris area. We performed a retrospective multicenter cohort study on the data warehouse of Greater Paris University Hospitals (AP-HP). We identified all patients newly referred with a PC between January 1, 2019, and June 30, 2021, and excluded endocrine tumors. Using claims data and health records, we analyzed the timeline of care trajectories, the initial tumor stage, the treatment categories: pancreatectomy, exclusive systemic therapy or exclusive best supportive care (BSC). We calculated patients' 1-year overall survival (OS) and compared indicators in 2019 and 2020 to 2021. We included 2335 patients. Referral fell by 29% during the first lockdown. The median time from biopsy and from first MDM to treatment were 25 days (16-50) and 21 days (11-40), respectively. Between 2019 and 2020 to 2021, the rate of metastatic tumors (36% vs 33%, P = .39), the pTNM distribution of the 464 cases with upfront tumor resection (P = .80), and the proportion of treatment categories did not vary: tumor resection (32% vs 33%), exclusive systemic therapy (49% vs 49%), exclusive BSC (19% vs 19%). The 1-year OS rates in 2019 vs 2020 to 2021 were 92% vs 89% (aHR = 1.42; 95% CI, 0.82-2.48), 52% vs 56% (aHR = 0.88; 95% CI, 0.73-1.08), 13% vs 10% (aHR = 1.00; 95% CI, 0.78-1.25), in the treatment categories, respectively. Despite an initial decrease in the number of new PCs, we did not observe any stage shift. OS did not vary significantly., (© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2023
- Full Text
- View/download PDF
7. The 10-month mortality rate among older patients treated for digestive system cancer during the first wave of the COVID-19 pandemic: The CADIGCOVAGE multicentre cohort study.
- Author
-
Aparicio T, Layese R, Hemery F, Tournigand C, Paillaud E, De Angelis N, Quero L, Ganne N, Prat F, Pachev A, Galula G, Benderra MA, and Canouï-Poitrine F
- Subjects
- Humans, Aged, 80 and over, Aged, Pandemics, SARS-CoV-2, Retrospective Studies, Cohort Studies, Communicable Disease Control, COVID-19, Digestive System Neoplasms
- Abstract
Introduction: The coronavirus disease 2019 (COVID-19) pandemic has had a dramatic impact on cancer diagnosis and care pathways. Here, we assessed the mid-term impact of the COVID-19 pandemic on older adults with cancer before, during and after the lockdown period in 2020., Materials and Methods: We performed a retrospective, observational, multicentre cohort study of prospectively collected electronic health records. All adults aged 65 or over and having been newly treated for a digestive system cancer in our institution between January 2018 until August 2020 were enrolled., Results: Data on 7,881 patients were analyzed. Although the overall 10-month mortality rate was similar in 2020 vs. 2018-2019, the mortality rate among for patients newly treated in the 2020 post-lockdown period was (after four months of follow-up) significantly higher. A subgroup analysis revealed higher mortality rates for (i) patients diagnosed in the emergency department during the pre-lockdown period, (ii) patients with small intestine cancer newly treated during the post-lockdown period, and (iii) patients having undergone surgery with curative intent during the post-lockdown period. However, when considering individuals newly treated during the lockdown period, we observed lower mortality rates for (i) patients aged 80 and over, (ii) patients with a biliary or pancreatic cancer, and (iii) patients diagnosed in the emergency department., Discussion: There was no overall increase in mortality among patients newly treated in 2020 vs. 2018-2019. Longer follow-up is needed to assess the consequences of the pandemic. A subgroup analysis revealed significant intergroup differences in mortality., Competing Interests: Declaration of Competing Interest All authors declare no conflicts of interest with regard to this study., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. Impact of two waves of Sars-Cov2 outbreak on the number, clinical presentation, care trajectories and survival of patients newly referred for a colorectal cancer: A French multicentric cohort study from a large group of university hospitals.
- Author
-
Kempf E, Priou S, Lamé G, Daniel C, Bellamine A, Sommacale D, Belkacemi Y, Bey R, Galula G, Taright N, Tannier X, Rance B, Flicoteaux R, Hemery F, Audureau E, Chatellier G, and Tournigand C
- Subjects
- Cohort Studies, Hospitals, University, Humans, Pandemics, RNA, Viral, Retrospective Studies, SARS-CoV-2, COVID-19 epidemiology, Colonic Neoplasms, Colorectal Neoplasms epidemiology, Colorectal Neoplasms therapy
- Abstract
The SARS-Cov2 may have impaired care trajectories, patient overall survival (OS), tumor stage at initial presentation for new colorectal cancer (CRC) cases. This study aimed at assessing those indicators before and after the beginning of the pandemic in France. In this retrospective cohort study, we collected prospectively the clinical data of the 11.4 million of patients referred to the Greater Paris University Hospitals (AP-HP). We identified new CRC cases between 1 January 2018 and 31 December 2020, and compared indicators for 2018-2019 to 2020. pTNM tumor stage was extracted from postoperative pathology reports for localized colon cancer, and metastatic status was extracted from CT-scan baseline text reports. Between 2018 and 2020, 3602 and 1083 new colon and rectal cancers were referred to the AP-HP, respectively. The 1-year OS rates reached 94%, 93% and 76% for new CRC patients undergoing a resection of the primary tumor, in 2018-2019, in 2020 without any Sars-Cov2 infection and in 2020 with a Sars-Cov2 infection, respectively (HR 3.78, 95% CI 2.1-7.1). For patients undergoing other kind of anticancer treatment, the percentages are 64%, 66% and 27% (HR 2.1, 95% CI 1.4-3.3). Tumor stage at initial presentation, emergency level of primary tumor resection, delays between the first multidisciplinary meeting and the first anticancer treatment did not differ over time. The SARS-Cov2 pandemic has been associated with less newly diagnosed CRC patients and worse 1-year OS rates attributable to the infection itself rather than to its impact on hospital care delivery or tumor stage at initial presentation., (© 2022 UICC.)
- Published
- 2022
- Full Text
- View/download PDF
9. Effect of lockdown on digestive system cancer care amongst older patients during the first wave of COVID-19: The CADIGCOVAGE multicentre cohort study.
- Author
-
Aparicio T, Layese R, Hemery F, Tournigand C, Paillaud E, De Angelis N, Quero L, Ganne N, Prat F, Pachev A, Galula G, Benderra MA, and Canouï-Poitrine F
- Subjects
- Aged, Aged, 80 and over, Communicable Disease Control, Female, Humans, Male, Pandemics, Paris epidemiology, Retrospective Studies, SARS-CoV-2, COVID-19 epidemiology, Digestive System Neoplasms epidemiology, Digestive System Neoplasms therapy, Health Services Accessibility
- Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has had a dramatic impact on cancer diagnosis and treatment. Most patients newly diagnosed with digestive system cancer are aged 65 and over., Methods: We performed a retrospective, observational, multicentre cohort study based on prospectively collected electronic health records. All adults aged 65 or over and having been newly treated for a digestive system cancer between January 2018 until August 2020 were enroled., Results: Data on 7882 patients were analysed. The first COVID-19 lockdown period led to a 42.4% decrease in newly treated digestive system cancers, and the post-lockdown period was associated with a 17% decrease. The decrease in newly treated digestive system cancer did not differ as a function of age, sex, comorbidities, primary tumour site, and disease stage. The proportion of patients admitted to an emergency department increased during the lockdown period. We do not observe a higher 3-month mortality rate in 2020, relative to the corresponding calendar periods in 2018 and 2019., Conclusion: To avoid a decrease in newly treated cancers during future lockdown periods, access to healthcare will have to be modified. Although 3-month mortality did not increase in any of the patient subgroups, the 2020 cohort must be followed up for long-term mortality., Competing Interests: Conflict of interest None declared., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
10. Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study.
- Author
-
Benderra MA, Aparicio A, Leblanc J, Wassermann D, Kempf E, Galula G, Bernaux M, Canellas A, Moreau T, Bellamine A, Spano JP, Daniel C, Champ J, Canouï-Poitrine F, Gligorov J, On Behalf Of The Ap-Hp/Universities/Inserm Covid-Research Collaboration, Cancer Ap-Hp Group Covid-Task Force, and Ap-Hp Covid Cdw Initiative Acci
- Abstract
Background: COVID-19 may be more frequent and more severe in cancer patients than in other individuals. Our aims were to assess the rate of COVID-19 in hospitalized cancer patients, to describe their demographic characteristics, clinical features and care trajectories, and to assess the mortality rate., Methods: This multicenter cohort study was based on the Electronic Health Records of the Assistance Publique-Hôpitaux de Paris (AP-HP). Cancer patients with a diagnosis of COVID-19 between 3 March and 19 May 2020 were included. Main outcome was all-cause mortality within 30 days of COVID-19 diagnosis., Results: A total of 29,141 cancer patients were identified and 7791 (27%) were tested for SARS-CoV-2. Of these, 1359 (17%) were COVID-19-positive and 1148 (84%) were hospitalized; 217 (19%) were admitted to an intensive care unit. The mortality rate was 33% (383 deaths). In multivariate analysis, mortality-related factors were male sex (aHR = 1.39 [95% CI: 1.07-1.81]), advanced age (78-86 y: aHR = 2.83 [95% CI: 1.78-4.51] vs. <66 y; 86-103 y: aHR = 2.61 [95% CI: 1.56-4.35] vs. <66 y), more than two comorbidities (aHR = 2.32 [95% CI: 1.41-3.83]) and C-reactive protein >20 ng/mL (aHR = 2.20 [95% CI: 1.70-2.86]). Primary brains tumors (aHR = 2.19 [95% CI: 1.08-4.44]) and lung cancer (aHR = 1.66 [95% CI: 1.02-2.70]) were associated with higher mortality. Risk of dying was lower among patients with metabolic comorbidities (aHR = 0.65 [95% CI: 0.50-0.84])., Conclusions: In a hospital-based setting, cancer patients with COVID-19 had a high mortality rate. This mortality was mainly driven by age, sex, number of comorbidities and presence of inflammation. This is the first cohort of cancer patients in which metabolic comorbidities were associated with a better outcome.
- Published
- 2021
- Full Text
- View/download PDF
11. New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown.
- Author
-
Kempf E, Lamé G, Layese R, Priou S, Chatellier G, Chaieb H, Benderra MA, Bellamine A, Bey R, Bréant S, Galula G, Taright N, Tannier X, Guyet T, Salamanca E, Audureau E, Daniel C, and Tournigand C
- Subjects
- Aged, Female, France epidemiology, Health Policy, Humans, Male, Middle Aged, Neoplasms diagnosis, Quarantine, SARS-CoV-2, COVID-19, Neoplasms epidemiology
- Abstract
Introduction: The dissemination of SARS-Cov2 may have delayed the diagnosis of new cancers. This study aimed at assessing the number of new cancers during and after the lockdown., Methods: We prospectively collected the clinical data of the 11.4 million patients referred to the Assistance Publique Hôpitaux de Paris Teaching Hospital. We identified new cancer cases between 1st January 2018 and 31st September 2020 and compared indicators for 2018 and 2019 to 2020 with a focus on the French lockdown (17th March to 11th May 2020) across cancer types and patient age classes., Results: Between January and September, 28,348, 27,272 and 23,734 new cancer cases were identified in 2018, 2019 and 2020, respectively. The monthly median number of new cases reached 3168 (interquartile range, IQR, 3027; 3282), 3054 (IQR 2945; 3127) and 2723 (IQR 2085; 2,863) in 2018, 2019 and 2020, respectively. From March 1st to May 31st, new cancer decreased by 30% in 2020 compared to the 2018-19 average; then by 9% from 1st June to 31st September. This evolution was consistent across all tumour types: -30% and -9% for colon, -27% and -6% for lung, -29% and -14% for breast, -33% and -12% for prostate cancers, respectively. For patients aged <70 years, the decrease of colorectal and breast new cancers in April between 2018 and 2019 average and 2020 reached 41% and 39%, respectively., Conclusion: The SARS-Cov2 pandemic led to a substantial decrease in new cancer cases. Delays in cancer diagnoses may affect clinical outcomes in the coming years., Competing Interests: Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
12. Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002.
- Author
-
Silvéra L, Galula G, Tiret E, Louvet C, Leroux JL, and Trutt B
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma pathology, Adenocarcinoma surgery, Adult, Age Factors, Aged, Aged, 80 and over, Colon pathology, Colonic Neoplasms drug therapy, Colonic Neoplasms pathology, Colonic Neoplasms surgery, Data Collection, Data Interpretation, Statistical, Female, Guideline Adherence, Humans, Liver Neoplasms secondary, Male, Middle Aged, Neoplasm Staging, Neoplasms, Multiple Primary therapy, Paris, Practice Guidelines as Topic, Retrospective Studies, Surveys and Questionnaires, Adenocarcinoma therapy, Colonic Neoplasms therapy
- Abstract
Objective: To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR)., Methods: This retrospective study carried out in 2003 by the Ile-de-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002., Results: In all, 1 842 patients were included; mean age was 68.7 +/- 12.7 years and the M/F ratio was 1.09. 17.3% of patients were diagnosed after complications (obstruction, perforation); 25.1% had synchronous metastases, 79.7% with at least one liver metastasis. Serum CEA assay was performed in 50.0% of patients, in combination with CA 19-9 in 31.1% of patients. In 24.9%, less than 8 lymph nodes were analyzed. 37.7% of stage II patients had chemotherapy while 10.8% of stage III and 9.8% of stage IV patients did not. Age was a determining factor in the decision of chemotherapy (P<0.0001)., Conclusion: Implementation of guidelines for the management of colon cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.
- Published
- 2006
- Full Text
- View/download PDF
13. Assessment of prescription practices for serological tests for viral hepatitis B and C in the Greater Parisian area in 2002.
- Author
-
Galula G, Buffet C, Robba L, and Poissonnet M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cross-Sectional Studies, Female, France, Humans, Infant, Insurance, Health, Reimbursement statistics & numerical data, Male, Middle Aged, Retrospective Studies, Guideline Adherence, Hepatitis B diagnosis, Hepatitis C diagnosis, Practice Guidelines as Topic, Practice Patterns, Physicians' statistics & numerical data, Serologic Tests statistics & numerical data
- Abstract
Objectives: The aim of this study was to ascertain the reasons for the prescription of serological tests for viral hepatitis B (HBV) and C (HCV) in the Greater Parisian area, and to assess standards of prescription with respect to current guidelines., Patients and Methods: The population studied comprised patients affiliated to the three main health insurance schemes in the Greater Parisian area, for whom at least one serological test for HBV or HCV was reimbursed on May 14th or 15th, 2002. Data was collected from prescribing and laboratory heads., Results: The sample consisted of 1 046 prescription orders for HBV and/or HCV tests. The mean age of patients was 39 years, and 68% were females. The main medical indications declared by the prescribing physicians were: screening for HBV or HCV (40%), tests for pregnant women (19%), suspected hepatitis B or C (13%), pre- and post-vaccination tests for HBV (7%), medically assisted procreation (6%), follow-up of diagnosed chronic hepatitis (4%). Assessment of the standards of prescription orders showed a lack of compliance with guidelines for 71% of HBV tests, and 56% of HCV tests., Conclusions: The implementation of guidelines for the prescription of serological tests for HBV and HCV needs to be improved in clinical practice.
- Published
- 2006
- Full Text
- View/download PDF
14. Herpes simplex esophagitis in patients with liver disease.
- Author
-
Pauwels A, Carbonell N, Galula G, Mohand-Mamar D, Maury E, de Lajarthe-Thirouard AS, Levy VG, and Poupon R
- Subjects
- Adult, Biopsy, Diagnosis, Differential, Esophagitis pathology, Esophagoscopy, Fatal Outcome, Female, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage pathology, Hepatic Encephalopathy pathology, Herpes Simplex pathology, Humans, Liver Cirrhosis, Alcoholic pathology, Liver Function Tests, Male, Middle Aged, Opportunistic Infections pathology, Ulcer diagnosis, Ulcer pathology, Esophagitis diagnosis, Hepatic Encephalopathy diagnosis, Herpes Simplex diagnosis, Liver Cirrhosis, Alcoholic diagnosis, Opportunistic Infections diagnosis
- Published
- 2002
- Full Text
- View/download PDF
15. Respective value of pudendal nerve terminal motor latency and anal sphincter electromyography in neurogenic fecal incontinence.
- Author
-
Thomas C, Lefaucheur JP, Galula G, de Parades V, Bourguignon J, and Atienza P
- Subjects
- Adult, Aged, Aged, 80 and over, Electric Stimulation, Electromyography, Fecal Incontinence etiology, Female, Humans, Manometry, Middle Aged, Postoperative Complications physiopathology, Prospective Studies, Anal Canal innervation, Anal Canal physiopathology, Fecal Incontinence physiopathology, Motor Neurons physiology, Peripheral Nerves physiopathology
- Abstract
Fecal incontinence may be related to a neurogenic injury. Electrodiagnostic tests including pudendal nerve terminal motor latency (PNTML) and external anal sphincter electromyography (AEMG) have been proposed to reveal anal nerve damage. The aim of this study was to assess the respective value of PNTML and AEMG in the diagnosis of fecal incontinence. This study included 80 women (range 23-85 years) with fecal incontinence secondary to obstetrical and/or surgical trauma. They were evaluated by performing PNTML and AEMG. The electrophysiological results were compared and interpreted in the light of anorectal manometry (ARM) results. Electrodiagnostic test abnormalities were found in 64 of 80 patients (80%), including 28 patients with abnormal results for both tests and 36 patients with only one abnormal test. Overall, a neurogenic AEMG pattern was found in 64% of patients and a prolonged PNTML in 51%. No correlation was found between PNTML value and either AEMG grade or ARM parameters, while AEMG grade strongly correlated with squeeze pressure measured by ARM. This study showed that AEMG and PNTML did not give redundant information and allowed to explicit the mechanisms of neurogenic fecal incontinence. We found that AEMG was more sensitive and more closely related to the anal functional status (ARM parameters) than PNTML. These electrodiagnostic tests, particularly AEMG as performed in everyday practice, are useful in the assessment of neurogenic fecal incontinence.
- Published
- 2002
- Full Text
- View/download PDF
16. [Klebsiella oxytoca-associated colitis after oral administration of fusidic acid].
- Author
-
Seksik P, Galula G, Maury E, Lévy VG, and Offenstadt G
- Subjects
- Acute Disease, Gastrointestinal Hemorrhage microbiology, Humans, Male, Middle Aged, Anti-Bacterial Agents adverse effects, Colitis microbiology, Fusidic Acid adverse effects, Klebsiella Infections etiology
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.